Ticagrelor reduces the growth of tumors in murine models of ovarian cancer. (A) Therapeutic schema for treatment with antiplatelet agents. (B) Representative images of tumors from each treatment groups. (C) Mean aggregate tumor weight. (D) Number of tumor nodules induced by intraperitoneal injection of A2780ip2 human ovarian cancer cells into nude mice treated with antiplatelet agents (n = 10 mice per group). (E) Quantification of Ki67-positive cells in resected tumors (n = 15 HPFs/5 mice per group). (F) CC3 quantification in control mice (red bars), mice treated with ticagrelor (blue bars), and mice treated with aspirin (green bars) (n = 15 HPFs/5 mice per group). (G) Effect of ticagrelor on the in vitro proliferation rate of A2780ip2 human ovarian cancer cells in the absence of platelets. (H) The effect of ticagrelor on the in vitro proliferation rate of A2780ip2, OVCAR8, OVCAR5, HeyA8, and OVCAR432 ovarian cancer cells in the absence and presence of platelets. Results are normalized to the proliferation rate of A2780ip2, OVCAR8, OVCAR5, HeyA8, and OVCAR432 in the absence of platelets and ticagrelor (n = 3 triplicate experiments).